Blis Technologies Limited

Blis Technologies Limited is rated 3 out of 5 in the category biotechnology. Read and write reviews about Blis Technologies Limited. Blis Technologies are the developers of the world’s first advanced oral probiotics. We currently market two strains of probiotic bacteria – BLIS K12™ and BLIS M18™ – both of which occur naturally in the oral cavity. However, only around 2% of the population have these healthy bacteria at levels high enough to be effective. BLIS K12™ was our first discovery. It was originally developed into a probiotic supplement to support throat health, but the benefits of BLIS K12™ have been found to be more wide-reaching as more studies have been completed. We know that BLIS K12™ has a positive impact on the ear nose and throat health of infants and children, and is also effective in improving bad breath (halitosis). The second strain BLIS M18™ was discovered later and this promotes a healthy bacterial balance for dental health. Both strains were discovered by Professor John Tagg while at the University of Otago Microbiology Department. Professor Tagg extensively catalogued a collection of more than 2000 of these bacteria strains over a period of more than 30 years. Those bacteria were then acquired by Blis Technologies with the first product – ThroatGuard – launched in 2002. Today the Blis portfolio consists of a range of products to support throat immunity, oral care, halitosis and travel immunity. All our products are developed and manufactured at our headquarters in Dunedin, New Zealand.